

Jakoba Johanna Eertink

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5312258/publications.pdf>

Version: 2024-02-01

14
papers

371
citations

1162367

8
h-index

1058022

14
g-index

15
all docs

15
docs citations

15
times ranked

156
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantitative Radiomics Features in Diffuse Large B-Cell Lymphoma: Does Segmentation Method Matter?. Journal of Nuclear Medicine, 2022, 63, 389-395.	2.8	16
2	18F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 932-942.	3.3	62
3	A Guide to ComBat Harmonization of Imaging Biomarkers in Multicenter Studies. Journal of Nuclear Medicine, 2022, 63, 172-179.	2.8	96
4	¹⁸ F-FDG PET Improves Baseline Clinical Predictors of Response in Diffuse Large B-Cell Lymphoma: The HOVON-84 Study. Journal of Nuclear Medicine, 2022, 63, 1001-1007.	2.8	12
5	The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in ¹⁸ F-FDG PET Scans of Patients with Classical Hodgkin Lymphoma. Journal of Nuclear Medicine, 2022, 63, 1424-1430.	2.8	20
6	Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index. Journal of Clinical Oncology, 2022, 40, 2352-2360.	0.8	53
7	Bloodâ€circulating EVâ€miRNAs, serum TARC, and quantitative FDGâ€PET features in classical Hodgkin lymphoma. EJHaem, 2022, 3, 908-912.	0.4	2
8	Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell Lymphoma: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium. Journal of Nuclear Medicine, 2021, 62, 332-337.	2.8	53
9	Interobserver Agreement on Automated Metabolic Tumor Volume Measurements of Deauville Score 4 and 5 Lesions at Interim ¹⁸ F-FDG PET in Diffuse Large B-Cell Lymphoma. Journal of Nuclear Medicine, 2021, 62, 1531-1536.	2.8	8
10	Not Yet Time to Abandon the Deauville Criteria in Diffuse Large B-Cell Lymphoma. Journal of Nuclear Medicine, 2021, 62, 1655.2-1656.	2.8	3
11	Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients. Blood Advances, 2021, 5, 2375-2384.	2.5	40
12	Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements. European Journal of Nuclear Medicine and Molecular Imaging, 2021, , 1.	3.3	4
13	Cost-effectiveness of shortening treatment duration based on interim PET outcome in patients with diffuse large B-cell lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.2	0
14	18f-FDG PET/CT Baseline Rdiomics Features Improve the Prediction of Treatment Outcome in Diffuse Large B-Cell Lymphoma Patients. Blood, 2020, 136, 27-28.	0.6	1